Allenex spins off NovaHep and Recopharma

Allenex spins off NovaHep and Recopharma

Allenex transfers its holdings in the portfolio companies NovaHep AB and
Recopharma AB to Alden Impact Capital AG, Zurich, who takes
responsibility for the continued financing of their activities.

In NovaHep, focusing on liver stem cells, has Allenex been shareholder
since 2005 and in Recopharma, with a focus on recombinant glyco
proteins, since 2003. Allenex has been the sole financier of the
companies' development work. Both companies have achieved valuable and
promising results while there is still much work to be done before they
can be commercialized.

Allenex focus is now on the transplantation sector and in terms of
liquidity the company prioritizes those activities. Agreement has now
been reached with Alden Impact Capital AG, Zurich, a Swiss private
equity manager linked to a family office, on the transfer of the
holdings in NovaHep and Recopharma. The agreement includes a part of the
future profits when Alden Impact Capital AG sells the holdings. Allenex
will report a small loss in the second quarter of 2011 of SEK 280
thousand. A greater impairment of the holdings took place during the
first quarter of 2011.

"Today, it is extremely difficult to find financing of the development
work carried out by NovaHep and Recopharma," says Anders Karlsson, CEO
of Allenex. "It is therefore very satisfying that we by the transfer to
Alden Impact Capital AG can ensure that both companies will be able to
continue their operations."

"NovaHep and Recopharma are two companies with a very exciting focus,"
says Stefan von Euw, Alden Impact Capital AG. "We will be able to
financially support the continued development and so reach the next
milestones."

Allenex AB discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 08:10 (CET) on August 25,
2011

For more information please contact:
Anders Karlsson, CEO Allenex AB tel: +4670-918 0010, email:
anders.karlsson@allenex.se
Okee Williams tel: tel +4670-60 053 64, email: okee.williams@allenex.se
Stefan von  Euw, Alden Impact Capital AG, tel: +41 79 277 7581, email:
stefan@aldencapital.ch

Or visit www.allenex.com. For more information about Alden Impact
Capital, please visit www.aldenimpact.com